DE1767196A1 - Soluble cancer antigens that are bound to foreign proteins - Google Patents
Soluble cancer antigens that are bound to foreign proteinsInfo
- Publication number
- DE1767196A1 DE1767196A1 DE19681767196 DE1767196A DE1767196A1 DE 1767196 A1 DE1767196 A1 DE 1767196A1 DE 19681767196 DE19681767196 DE 19681767196 DE 1767196 A DE1767196 A DE 1767196A DE 1767196 A1 DE1767196 A1 DE 1767196A1
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- soluble
- link
- means according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 41
- 239000000427 antigen Substances 0.000 title claims description 35
- 102000036639 antigens Human genes 0.000 title claims description 35
- 108091007433 antigens Proteins 0.000 title claims description 35
- 201000011510 cancer Diseases 0.000 title claims description 29
- 102000004169 proteins and genes Human genes 0.000 title claims description 18
- 108090000623 proteins and genes Proteins 0.000 title claims description 18
- 239000000126 substance Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 5
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 p-diamino-diphenyl compound Chemical class 0.000 claims 2
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000012954 diazonium Substances 0.000 claims 1
- 150000001989 diazonium salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108010074605 gamma-Globulins Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101000693911 Equus caballus Albumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000798077 Poelagus marjorita Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 101150068006 phoB gene Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Lösliche Krebsantigene, die an Sremdproteine gebunden sindSoluble cancer antigens bound to foreign proteins
Die vorliegende Erfindung betrifft lösliche, an Fremdproteine gebundene Krebs- oder anomale Krankheitsantigene und entsprechende Herstellung*- und Anwendungemethoden, insbesondere lösliche Krebsantigene, wie menschliche Tumor- und Leukämie-Antigenö, die an Tresdproteine, wie animalische ßarama-Ölobulin©, gebunden sind mittels eines chemischen Bindegliedes, wie bls-diaeotisier-tes Benzidin.The present invention relates to soluble, foreign protein bound cancer or abnormal disease antigens and the like Production * and application methods, especially soluble ones Cancer antigens, such as human tumor and leukemia antigens, bound to Tresdproteins such as animal ßarama-Ölobulin © are by means of a chemical link such as bls-diaeotisier-tes Benzidine.
Das vorgenannte Mittel, das ein lösliches Krebsantigen enthält, wird als Impfstoff oder Heilmittel bei an Krebs erkrankten Menschen angewendet,The aforementioned agent, which contains a soluble cancer antigen, is used as a vaccine or remedy in people with cancer applied,
In vielen Fällen, wie bei Krebskrankheit eines Menschen, ist es sehr erwünscht, den Körper des Patienten sum Kampf gegen die Krankheit anzuregen. Venn ein gebundener Stoff verwendet wird, wirkt dieser in seiner Gesamtheit wie ein Antigen, welches ImIn many cases, as with human cancer, it is very desirable to have the patient's body fight against the To stimulate disease. When a bound substance is used, it acts in its entirety like an antigen, which Im
209828/1027209828/1027
BAD ORIGINALBATH ORIGINAL
1767198 i1767198 i
A-55 145 .A-55 145.
Patienten Antikörper ssu erzeugen scheint, die die Krebsantigene des Patienten bekämpfen*Patients appear to generate antibodies that represent the cancer antigens fight the patient *
Sie Erfindung betrifft einen gebundenen Impfet off für Krebskranke oder Kranke bei denen Krebsverdacht besteht, welcher unerwünschte Heben-Wirkungen veraindert und dennoch das fortschreiten der Krankheit verhindert oder zumindest verlangsamt. Sie betrifft auch einen w gebundenen Ispfetoff und/oder ein solches Heilmittel, der/das wirksam ist und weniger Hebenwirkungen hervorruft als andere ge» buttdene Stoffe. Weiterhin betrifft die Erfindung einen gebundenen Impfstoff und ein entsprechendes Herstellungsverfahren, wobei ein lösliches Krebsantigen ein Bestandteil dieses gebundenen Impfstoffes ist. Schliesslich betrifft die Erfindung einen gebundenen Impfstoffkomplex und ein Herstellungsverfahren dafür, wobei ein lösliches Krebsantigen, wie $umor- oder Lenkamiegewebe, dasThe invention relates to a bound vaccine for cancer patients or those who are suspected of having cancer, which vaccinates undesirable lifting effects and yet prevents or at least slows down the progression of the disease. It also relates to a w bound Ispfetoff and / or such a remedy, the / is the effective and less lifting effects causes than other ge "butt dene substances. The invention further relates to a bound vaccine and a corresponding production method, a soluble cancer antigen being a component of this bound vaccine. Finally, the invention relates to a bound vaccine complex and a production method for the same, wherein a soluble cancer antigen, such as tumor or stenosis tissue, the vom Patienten und/oder von änderen Patienten bezogen wurde» an ein Trendprotein, wie Kaninchen-Gamma-Globulin, gebunden wird Mittels eines chemischen Bindegliedes wie bis-dlezotisiertes Benzidin. (Löslich wird definiert als die Fähigkeit, sich in wässrigen Löeungen, wie physiologischen oder gepufferten Salzlösungen, aufzulösen. )obtained from the patient and / or from other patients is bound to a trending protein such as rabbit gamma globulin a chemical link such as bis-dlezotized benzidine. (Soluble is defined as the ability to dissolve in aqueous solutions such as physiological or buffered saline solutions.)
Die Erfindung liefert einen neuen gebundenen Impfstoffkomplex, in welchem ein lösliches Krebsantigen mittels eines chemischen Bindegliedes, wie bis-diazotisiertes Bonzidin, an ein Premdprotein gebunden ist»The invention provides a new linked vaccine complex, in which a soluble cancer antigen is bound to a premd protein by means of a chemical link such as bis-diazotized bonzidin »
209828/1027209828/1027
— 2 -- 2 -
BAD ORIGINALBATH ORIGINAL
A-55 H5A-55 H5
Zu geeigneten löslichen Krebsantigenen zählen homogenisierte, löeliche, osnceröse auto-und/oder ieogene menschliche Gewebeantigene, wie menschliche Leukämie- und Tumorantigene, welche aus Leukämie- oder Tumorgeweben gewonnen worden sind wad ale ZeIlagglomerat betrachtet werden können« Diese löslichen Krebsantigene werden nach de» in der USA-Patentschrift 3 065 141 beschriebenen Verfahren hergestellt. Die löslichen Krebsantigene werden gewonnen aus der Fliiorkohlenot off-Extrakt ionnechieht, die das undenaturierte Hucleoprotein enthält. Die Homogenisierung wird vorzugsweise bei hoher Geschwindigkeit, z. B. von mindestens etwa 23000 UpM, und in der Kälte, e. B. bei ca. 0° bis 4° C, durchgeführt. Im allgemeinen werden mindestens drei, vorzugsweise sechs bis sehn Homogenlsierunga- oder Trennzyklon vorgenommen, um Aas gewünschte lösliche Krebsantigen su erhalten.Suitable soluble cancer antigens include homogenized, soluble, osseous autogenous and / or ieogenic human tissue antigens, such as human leukemia and tumor antigens, which have been obtained from leukemia or tumor tissues because all cell glomerates can be considered in U.S. Patent 3,065,141. The soluble cancer antigens are obtained from the fluorocarbon extract, which contains the undenatured hucleoprotein. The homogenization is preferably carried out at high speed, e.g. B. at least about 23,000 rpm, and in the cold, e. B. at about 0 ° to 4 ° C carried out. In general, at least three, preferably six to ten, homogenization or separation cyclones are carried out in order to obtain the desired soluble cancer antigen.
Die cancerösen menschlichen Antigene werden gebunden an Proteine » die Fremd proteinen, z. B. von Kaninchen, Pferden, Schafen und vielerlei anderen animalisohen und nicht animalischen Proteinen, entstammen. Zu solchen Proteinen gehören z. B. Kaninchen-Gamma-Globulin, Kaninchenalbumin, Pford-Gamma-Globulin, Pferdalbumin, Schaf-Gamma-Globulin, S chef albumin imii Eialfciuain. Dio Gewinnung dieser Proteine und deren Reinigung ist beferant; rlieLe Proteine sind im Handel erhältlich.The cancerous human antigens are bound to proteins »the foreign proteins, z. B. from rabbits, horses, sheep and many other animal and non-animal proteins. Such proteins include e.g. B. rabbit gamma globulin, rabbit albumin, pford gamma globulin, horse albumin, sheep gamma globulin, S chef albumin imii Eialfciuain. The extraction of these proteins and their purification is important; All proteins are commercially available.
vreitem vorgesogen. Andere» ele cheiai?iol?.-2svreitem pre-drawn. Others »ele cheiai? Iol? .- 2s
209828/1027209828/1027
A-55 H5A-55 H5
Diamine sind:Diamines are:
313'-Dimöthylbenzidin 3,3*-Diehlorbenzidin313'-dimethylbenzidine 3,3 * -diehlobenzidine
α, α ♦ -Bis-p-boluidinα, α ♦ -Bis-p-boluidine
Obwohl nan ale Fremdprotein ein hetorogeneo Protein oder Antigen, wie Gamraaglobulin von Pferden, Kanirchen oöer andere Gaaoaaglobtiline, die kvsine allauat&rlcen Nebenwirkungen im Patienten hervorrufen, verwenden kann, bororaiigt xnar. ein Xanincfceü-GaiOT'a-Glofcu« lin, wie dar? eog. Cohn-Practicn-II-Fa'o.inc^en-QaTniiia-Globulin. Bus Extraktioris·Vorfahren von Gdhn fraction II wird T>GEöt?ri.eben Ten 15. J. Cohn :.m Journal of the Atnericni Cenccv Society, B^ad 6t· 0946), Soice 459.Although all foreign proteins can use a heterogeneous protein or antigen, such as gamraaglobulin from horses, Kanirchen or other gaaoaaglobtiline, which cause side effects in the patient, bororaiigt xnar. a Xanincfceü-GaiOT'a-Glofcu «lin, how is that? eog. Cohn-Practicn-II-Fa'o.inc ^ en-QaTniiia-Globulin. Bus Extraktioris ancestors of Gdhn fraction II becomes T> GEöt? Ri .eben Ten 15. J. Cohn : .m Journal of the Atnericni Cenccv Society, B ^ ad 6t 0946), Soice 459.
"5. _e _i a jo i Q 1"5. _e _i a jo i Q 1
An 61,364- W, bio-diaaotioiertes 3ßn£iö?.rx irurder. ein ErcbsantJecn und ein Κεηίiciien-GuKJBE-Gloimlin *&Runden, wo"bei τι eine Lüimng von BOG rat? dee Krebs ancigtraa ir. 100 al 0,9-ge*An 61,364- W, bio-diaaotioated 3ßn £ iö? .Rx irurder. an ErcbsantJecn and a Κεηίiciien-GuKJBE-Gloimlin * & Runden, where "at τι a liaison from BOG ra t ? dee Krebs an cigtraa ir. 100 al 0.9-ge *
209828/1027209828/1027
BAD ORIGINALBATH ORIGINAL
Α-55 Η5Α-55 Η5
wichtsprozentiger ffatritiischloricllösung und von 800 sag Oohn-Praction-II-Kaninehen-ßaaffiia-GloImlin in 100 ml 0t9#iger Hatriu»- ehloridlösung verwendete. Das lrisliche Erebsantigen wurde aus isogenem Tumorgewebe als Ausgau^smateriGl gewonnen. Dieses üfuraoz1-gewebe war ein Aggregat aus Tumoren von über 100 Patienten. Bas Tumorgewebe wurde in eine phospliatgepiAfferte Salslösung von pH 7,2 gegeben und mindestens drelssal in einem Pluorli-olslenatoff-Verdünnungsmittel (Trichlcrfluo^äthan) bei 5000. VvHl und 2° C homogenisiert. Der den Bucleoproteintoil öcr homogenisierten M-flchung enthaltende FluorkohlensSoffauazug liefert© das lösliche Krebsartigen, während die in der was or igen S chi eilt enthaltene Hucleinsäure gemSss der in der vorher genatinton :?atont3chrift beschriebenen Methode entfernt ^rurde. Dae ITucleo;33?otein der Fluorkohlenstoffschicht wurde in phoB^hatgcpiiffereuer Salzlösung gelöst, daraus ausgefällt, lyophilioiwfc ßu öinca Pulver und wieder in Lösung gebracht, so dass Kami so des lösliche Krcbc&nti-gen des Auagangsmaterials erhielt.weight percent ffatritiischloricllösung and 800 tell Oohn-Praction II Kaninehen-ßaaffiia-GloImlin in 100 ml t 0 9 # hydrochloric Hatriu "- ehloridlösung used. The irish erebsantigen was obtained from isogenic tumor tissue as a source of material. This üfuraoz 1 tissue was an aggregate of tumors from over 100 patients. The tumor tissue was placed in a phosphate-coated saline solution of pH 7.2 and homogenized at least three times in a fluorine-olefin diluent (trichlorethylene) at 5000 VvHl and 2 ° C. The fluorocarbon soffau acid containing the buccleoprotein oil or the homogenized M-flattening supplies the soluble cancerous substance, while the hucleic acid contained in the former was removed according to the method described in the genatinton: aton pamphlet. The ITucleo; 33? Otein the fluorocarbon layer was dissolved in phoB ^ hatgcpiiffereuer salt solution, precipitated therefrom, lyophilioiwfc ßu öinca powder and brought back into solution, so that Kami so obtained the soluble contents of the starting material.
Zu Beginn wurden die beiden Proteine, das Krebsratigen und das Gamma-Globulin, gemischt, und unter eijändigem Hüiiren *rordc langsam angesäuertes bis-diazotisiertes Bonzidin zugegeben. Bei der Zugabe des bis-diaeotisierton Benzidins koagulierto das ProdulctIn the beginning, the two proteins, the cancer rate and the Gamma-globulin, mixed, and slowly acidified bis-diazotized bonzidin added while heating with hands. In the Addition of the bis-diaeotized benzidine coagulates the product
* und nach weiterem Umrühren liesß eicfe ein bräunlicher Proteinni·- derschlag feststellen, der offensichtlich ein Komplex aus Krebsartigen, bis-diazotisiertem Bensidin und Gaimaa-Globulin war.* and after further stirring eicfe left a brownish protein ni · - found the strike, which was apparently a complex of cancerous, bis-diazotized bensidine and Gaimaa globulin.
209828/1027209828/1027
BAD ORIGINALBATH ORIGINAL
T7S7196T7S7196
A-55 H5A-55 H5
Hierauf dialysierto man die Mischung aue niederschlag und Schwimmschicht in einer Cellulosaacetat-Dialysenmembran gegen dae zwanzig- oder über zwanzigfache Volumen von O,9#igera Chlorid und 1 10 000 Merthiolat, einem bakteric statischen Kittel.The mixture is then dialyzed to form a precipitate and a floating layer in a cellulose acetate dialysis membrane against the twenty or more than twenty times the volume of 0.9% chloride and 1 10,000 merthiolate, a bacteric static gown.
Sas Dialysat wurde 5mal gewechselt. Hach dem 5. Vecheel konnte mit ultravioletter Sj&ektrophotorüeuria kein tiberaehüoeigeß biediazotisiertes Benzidin mehr im Dialysat nachgewiesen werden.Sas dialysate was changed 5 times. Hach the 5th Vecheel could with ultraviolet Sj & ektrophotorüeuria no more tiberaehüoeigeß biediazotized benzidine can be detected in the dialysate.
Das so erhaltene gebundene Kittel ist ein löslichor Komplex aus Krebsantigen, bia-diazotiaiertecn Bonsidin und Ganraa-Globulin, · welcher sich verwenden lässt, um beiepiolttweise monscb.licho Patienten gegen Krebs zu impfen, odar als therapeutischer Wirkstoff zur Behandlung Krebskranker. Di? Heilwirkung bestand darin, dass doe Fortschreiten der Krankheit im Patienten eingodfitHBt oder zumindest verlangsamt wurde.The bonded gown thus obtained is a soluble complex of Cancer antigen, bia-diazotized bonsidin and ganra-globulin, which can be used to vaccinate monscb.licho patients against cancer, or as a therapeutic agent for the treatment of cancer patients. Di? The healing effect was that the progression of the disease in the patient was stopped or at least slowed down.
Der objektive Heilwert wurde gemessen durch Titrieren des Serums dee Patienten gegen Anti-Krebe-Pferdeplasma, sowie durch Titrieren prä-immunisierten und post-imsnmisierten menephlichen Serums gegen eine 1^ige Lösung sieneohliehen Tumorant^gens und eine 1#ige Lösung normalen menschlichen Antigene la Verlauf ejknes dlagnostisohen Tests. Jegliches Abnehmen oder Wegfallen dee Titera* gegen das Antikrebs-Pf erdeplasica war von einer klinischen Beose-The objective healing value was measured by titrating the serum dee patients against anti-cancer equine plasma, as well as by titrating pre-immunized and post-immunized menephial serum Against a 1% solution, use tumor antigen and a 1% solution Solution normal human antigens la course ejknes dlagnostisohen tests. Any decrease or omission of the Titera * against the anticancer Pf erdeplasica was from a clinical investigation
rung des Patienten begleitet. Desgleichen war eine Titorfc des pnst-imnunlsierten menschlichen Serums gegen denmentation of the patient. Likewise was a Titorfc of the pnst-immunized human serum against the
209828/1027209828/1027
A-55 145A-55 145
Impfkoaplex und/oder άβοοβη Komponenten im allgemeinon ron klinischer Besserung der Patienten begleitet.Vaccine complex and / or άβοοβη components generally accompanied by clinical improvement of the patient.
Im Torgenannten Beispiel kann euch ein aus leukätnisehea Gewebe anstatt sue Tumorgewebe gewonnenes lösliches Krebsantigen verwendet werden, wobei ähnliche Ergebnisse erzielt werden.In the example mentioned gate you can get a leukätnisehea tissue soluble cancer antigen obtained instead of sue tumor tissue, with similar results being obtained.
Gewinnt »an lösliches undenaturiertos anomales Antigen nicht aus Krebsgewebe, sondern aus den Gewebe bei anderen anomalen Krankheiten oder bösartigen Wucherungen, a. B. bei Arterienverkalkung, ao wird der erhaltene lösliche Antigen-Fremdproteln-Koaplex als Impfstoff gegen nicht-krebsartige anomale Krankheiten oder als therapeutischer Wirkstoff sur Behandlung derselben benutzt.Obtains “soluble, undenatured abnormal antigen not from cancerous tissue, but from the tissues of other abnormal diseases or malignant growths, a. B. in hardening of the arteries, ao the resulting soluble antigen-foreign protein complex is used as a vaccine against non-cancerous abnormal diseases or as a therapeutic agent sur the treatment of the same.
Es bestehen Anzeichen, dass der gebundene Iapfatoffkonplex den Patienten anregt, in seinen Blute Antikörper zu produzieren gegen den Impfstoffkomplex und jede seiner Komponenten, näelich gegen die löslichen menschlichen Krebsantigene und das Freedprotein im Komplex. Jene Antikörper gegen menschlichen Tumor und gegen Kaninchen-Gamma-Globulin lassen sich im Servp geimpfter Patienten nachweisen, wenn man ihr Serum gegen den Iapf stoff und jede seiner Komponenten (lösliches menschliches Krebsantigen und löslich©β Kaninchen-Oamaa-Globulin) titriert· BIe auf BOlche Weise entwickelten Antikörper »oheinen die Krebsantigene im Patienten anzugreifen, also die 7uBorantigeno unö den Tumor selbst * Ku bekämpfen, und dadurch dossrm Wachstuasgeachwindigkoit asu verlangosrjen oder gar au völligem Stillstand zu bringen.There are signs that the bound Iapfatoffkonplex den Encourages the patient to produce antibodies in their blood against the vaccine complex and each of its components against the soluble human cancer antigens and the Freed protein in the complex. Those antibodies against human tumor and against rabbit gamma globulin can be vaccinated in the Servp Patients can prove that their serum is against the vaccine and each of its components (soluble human cancer antigen and soluble (β Rabbit Oamaa Globulin) titrated BIe on BOlche Antibodies developed in a way that do not attack the cancer antigens in the patient, that is, the boron antigens do not harm the tumor itself * Fight Ku, and thereby dossrm growth rate windigkoit asu to slow it down or even to bring it to a complete standstill.
20982^/102720982 ^ / 1027
Claims (12)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62992467A | 1967-04-11 | 1967-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1767196A1 true DE1767196A1 (en) | 1972-07-06 |
Family
ID=24525038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681767196 Pending DE1767196A1 (en) | 1967-04-11 | 1968-04-10 | Soluble cancer antigens that are bound to foreign proteins |
Country Status (4)
| Country | Link |
|---|---|
| AT (1) | AT281286B (en) |
| DE (1) | DE1767196A1 (en) |
| FR (1) | FR7473M (en) |
| GB (1) | GB1193378A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2822731A1 (en) * | 1978-04-20 | 1979-10-31 | Duncan Lee Mccollester | VACCINE FOR IMMUNOTHERAPY NEOPLASTIC DISEASES |
| DE3513572A1 (en) * | 1985-04-16 | 1986-10-16 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Preparation of products for specifically influencing the humoral and cellular immune response |
| EP1002936A2 (en) | 1998-11-18 | 2000-05-24 | Siemens Aktiengesellschaft | Process for preheating condensate in a feed water tank of a steam power plant |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201112A (en) * | 1981-10-01 | 1986-10-08 | Otsuka Pharma Co Ltd | Preparation of a cancer-specific antigen and composition |
| JPS58187861A (en) * | 1982-04-26 | 1983-11-02 | Otsuka Pharmaceut Co Ltd | Assay of antibody related to adult type t leukemia |
| US6294172B1 (en) * | 1983-08-12 | 2001-09-25 | Dade Behring Marburg Gmbh | Monoclonal antibodies with specificity for membrane-associated antigens |
| DE3909799A1 (en) | 1989-03-24 | 1990-09-27 | Behringwerke Ag | MONOCLONAL ANTIBODIES (MAK) AGAINST TUMOR ASSOCIATED ANTIGENS, THEIR PRODUCTION AND USE |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
-
1968
- 1968-03-15 GB GB02762/68A patent/GB1193378A/en not_active Expired
- 1968-04-10 AT AT354568A patent/AT281286B/en not_active IP Right Cessation
- 1968-04-10 DE DE19681767196 patent/DE1767196A1/en active Pending
- 1968-04-11 FR FR147735A patent/FR7473M/fr not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2822731A1 (en) * | 1978-04-20 | 1979-10-31 | Duncan Lee Mccollester | VACCINE FOR IMMUNOTHERAPY NEOPLASTIC DISEASES |
| DE3513572A1 (en) * | 1985-04-16 | 1986-10-16 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Preparation of products for specifically influencing the humoral and cellular immune response |
| EP1002936A2 (en) | 1998-11-18 | 2000-05-24 | Siemens Aktiengesellschaft | Process for preheating condensate in a feed water tank of a steam power plant |
Also Published As
| Publication number | Publication date |
|---|---|
| AT281286B (en) | 1970-05-11 |
| FR7473M (en) | 1969-12-01 |
| GB1193378A (en) | 1970-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2806146C2 (en) | Tumor-specific glycoprotein and its use for cancer diagnosis in humans | |
| DE3806565C2 (en) | ||
| DE1927209A1 (en) | Acyl-substituted insulins and processes for their preparation | |
| DE112011102411T5 (en) | A method of treating attention deficit hyperactivity disorder | |
| DE1767196A1 (en) | Soluble cancer antigens that are bound to foreign proteins | |
| DE2751454A1 (en) | CONTROL AND REVERSAL OF IMMUNOLOGICAL AGING | |
| DE2010788A1 (en) | Antigenic substances insoluble in water and process for their preparation | |
| DE2814121C3 (en) | Process for the preparation of a specific immune serum useful in cancer diagnosis K K Saikin Kagaku Kenkyujo, Sendaishi | |
| DE3917852A1 (en) | MEDICINES FOR TUMOR THERAPY WITH CONTROLLED AND REGULATED IMMUNE SYSTEM AND USE OF THE INDIVIDUAL SUBSTANCES FOR COMBINED THERAPY | |
| DE2039223C3 (en) | Parenterally injectable pharmaceutical preparation containing a parenterally compatible carrier material and a desensitizing agent against allergies | |
| DE2327687A1 (en) | ANTISEPTIC MEDIUM | |
| DE3250068C2 (en) | ||
| DE2713680A1 (en) | PROCESS FOR MANUFACTURING AN AGENT HAVING MITOGENIC AND / OR ADJUVANIC PROPERTIES AND MEDICINAL PRODUCTS CONTAINING THIS AGENT | |
| DE10007771A1 (en) | Immunomodulatory compositions, processes for their preparation and their use | |
| DE960579C (en) | Process for the production of a heat-sterilizable adrenocorticotropin preparation | |
| DE1617344A1 (en) | Method for producing a tetanus vaccine | |
| DE4122906A1 (en) | Divested bacteria prepn. for vaccines - by binding partially oxidised polysaccharide to surface, and coating modified bacteria with viral or bacterial protein or polypeptide | |
| DE4238766A1 (en) | New inter-species antibodies reactive with cellular antigens - present in all mammals and birds under conditions of stress, useful for treating, preventing or diagnosing e.g. tumours or virus diseases | |
| DE3032606A1 (en) | Thrombolytic streptokinase polysaccharide deriv. - prepd. by reacting pre:oxidised dextran with streptokinase, then reducing | |
| DE112009002431T5 (en) | Application of Fc fragments of immunoglobulin G as an antigen for the treatment of rheumatoid arthritis, treatment agents and methods of treatment | |
| DE2630380A1 (en) | PROCESS FOR MANUFACTURING A VACZINE | |
| DE2425678A1 (en) | METHOD OF MANUFACTURING A VACCINE AGAINST INFECTIOUS HORSE ANEMIC | |
| DE1818054C2 (en) | Process for the production of cytobiotic globulins | |
| DE238162C (en) | ||
| DE1617886A1 (en) | Process for the preparation of drugs with selective tropism against cancer and certain organs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |